CBD and CBG May Reverse Fatty Liver Disease, Groundbreaking Hebrew University Study Finds
Advertisement
A groundbreaking study from the Hebrew University of Jerusalem has revealed that two of the most widely available cannabinoids — CBD and CBG — may hold the key to combating one of the world's most prevalent metabolic conditions. Published in the British Journal of Pharmacology in March 2026, the research demonstrates that cannabidiol (CBD) and cannabigerol (CBG) can improve liver health through two distinct biological mechanisms, offering new hope for the estimated one-third of adults worldwide affected by fatty liver disease.
The study, led by Prof. Joseph Tam, Dr. Liad Hinden, and PhD student Radka Kočvarová at the School of Pharmacy within the Faculty of Medicine, provides the most detailed picture yet of how these non-intoxicating cannabis compounds interact with liver cells at the molecular level — and why they may succeed where many pharmaceutical approaches have fallen short.
Key Takeaways
- CBD and CBG improve liver health through two mechanisms: boosting cellular energy reserves via phosphocreatine and reactivating the lysosomal cleanup system through cathepsin enzymes
- The study, published in the British Journal of Pharmacology, found major reductions in triglycerides and ceramides — lipids central to fatty liver disease progression
- CBG outperformed CBD in reducing body fat, improving insulin sensitivity, and normalizing cholesterol levels
Table of Contents
- Understanding Fatty Liver Disease
- Mechanism One: The Emergency Energy Supply
- Mechanism Two: Restoring the Cellular Cleanup System
- CBG Shows Distinct Advantages
- Why This Matters for Millions
- What Consumers Should Know
- The Road Ahead
Understanding Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly known as non-alcoholic fatty liver disease or NAFLD), has become a global health epidemic that receives far less attention than its prevalence warrants. Affecting roughly one in three adults worldwide, MASLD occurs when excess fat accumulates in liver cells, impairing the organ's ability to process nutrients, filter toxins, and regulate metabolism.
Left untreated, MASLD can progress through several increasingly dangerous stages: simple fat accumulation gives way to inflammation (steatohepatitis), which can lead to scarring (fibrosis), cirrhosis, and ultimately liver failure or liver cancer. The condition is closely linked to obesity, type 2 diabetes, and metabolic syndrome, and its prevalence has been climbing alongside global rates of these conditions.
What makes MASLD particularly challenging from a treatment perspective is the lack of widely approved pharmaceutical therapies. While lifestyle modifications — diet, exercise, and weight management — remain the primary treatment recommendation, many patients struggle to achieve and maintain the changes necessary for meaningful improvement. The medical community has been actively searching for pharmacological interventions that can address the underlying cellular dysfunction driving the disease.
Mechanism One: The Emergency Energy Supply
The Hebrew University team discovered that CBD and CBG activate a previously underappreciated metabolic pathway in liver cells. Both compounds increased levels of phosphocreatine, a molecule that functions as an emergency energy supply within cells.
Think of phosphocreatine as a cellular battery backup. Under normal conditions, liver cells generate energy through standard metabolic processes. But when cells are under stress — as they are in fatty liver disease, where excess lipids disrupt normal function — they need an additional energy source to maintain critical operations.
Phosphocreatine provides exactly this, offering a rapid-release energy reserve that cells can tap into when their primary energy systems are compromised.
By boosting phosphocreatine levels, CBD and CBG essentially gave stressed liver cells the extra energy they needed to resume normal function. This included the energy-intensive processes involved in breaking down and eliminating the excess fat that defines fatty liver disease. The finding suggests that one reason fatty liver disease progresses is not just that liver cells accumulate too much fat, but that they lack the energy resources to deal with it — and cannabinoids may help restore that balance.
Mechanism Two: Restoring the Cellular Cleanup System
The second mechanism the researchers identified was equally compelling. CBD and CBG were shown to reactivate cathepsins — specialized enzymes that operate within lysosomes, the cellular structures responsible for breaking down and recycling damaged or unnecessary materials.
Lysosomes are often described as the cell's waste disposal system. When functioning properly, they break down everything from damaged proteins to excess lipids, keeping the cell clean and operational. In fatty liver disease, the lysosomal system becomes overwhelmed and dysfunctional.
Cathepsin activity drops, damaged materials accumulate, and the cell's internal environment deteriorates.
The Hebrew University study showed that CBD and CBG reactivated these cathepsin enzymes, effectively restarting the cellular cleanup process. The result was dramatic: major reductions in damaging lipid molecules including triglycerides and ceramides — two types of fats that play central roles in liver disease progression. By restoring the cell's ability to clean up after itself, the cannabinoids addressed one of the fundamental cellular breakdowns underlying MASLD.
CBG Shows Distinct Advantages
While both CBD and CBG demonstrated beneficial effects on liver health, the study revealed important differences between the two compounds that could have significant implications for therapeutic development.
CBG showed stronger effects in several key metabolic markers. Compared to CBD, CBG produced greater reductions in body fat, more significant improvements in insulin sensitivity, and better cholesterol profiles. Both compounds improved blood sugar control, but CBG's superior performance across multiple metabolic indicators suggests it may be the more potent therapeutic candidate for metabolic liver disease.
This finding is particularly noteworthy because CBG has received far less commercial and research attention than CBD. Often called the "mother cannabinoid" because it is the chemical precursor from which other cannabinoids are synthesized in the cannabis plant, CBG has traditionally been present only in small concentrations in most cannabis varieties. However, recent advances in cannabis breeding and extraction have made CBG products increasingly available to consumers, and this research could accelerate that trend considerably.
Why This Matters for Millions
The potential implications of this research are enormous simply because of the scale of the problem it addresses. With roughly 2 billion adults worldwide affected by some degree of fatty liver disease, even a modestly effective cannabinoid-based treatment could represent one of the most significant therapeutic developments in metabolic medicine.
Current treatment options are limited. The FDA has approved only a handful of drugs for liver disease-related conditions, and most existing therapies target downstream effects rather than the cellular dysfunction driving fat accumulation. A treatment that simultaneously boosts cellular energy reserves and restores waste disposal systems would address the disease at a more fundamental level than most current approaches.
Moreover, CBD and CBG have well-established safety profiles relative to many pharmaceutical alternatives. Both compounds are non-intoxicating, widely available, and generally well-tolerated, with far fewer side effects than many drugs used to manage metabolic conditions. While the Hebrew University researchers emphasized that further human clinical trials are needed before therapeutic recommendations can be made, the existing safety data on these compounds could accelerate the path from laboratory findings to clinical application.
What Consumers Should Know
For the millions of people already using CBD products for various health reasons, this study adds a potentially important new dimension to the conversation about cannabinoid supplementation. However, several important caveats apply.
First, the research was conducted using laboratory models, not human clinical trials. While the mechanisms identified are biologically plausible and the results are promising, the translation from laboratory to clinical efficacy is never guaranteed. Human studies will need to confirm the findings and establish optimal dosing, duration, and formulation before clinical recommendations can be made.
Second, the quality of commercially available CBD and CBG products varies enormously. Consumers interested in these cannabinoids for liver health should prioritize products from reputable manufacturers that provide third-party laboratory testing results confirming cannabinoid content and the absence of contaminants like heavy metals, pesticides, and residual solvents.
Third, anyone with existing liver conditions should consult their healthcare provider before adding cannabinoid supplements to their regimen. CBD in particular is metabolized by the liver and can interact with certain medications, including some commonly prescribed for metabolic conditions.
The Road Ahead
The Hebrew University study represents an important step in understanding how cannabinoids interact with metabolic systems, but it is just the beginning. The researchers have identified two specific molecular pathways through which CBD and CBG improve liver health, providing clear targets for future studies and potential drug development.
Clinical trials in human patients will be the next critical milestone. If the laboratory findings translate to meaningful clinical benefits, cannabinoid-based liver treatments could be available within a few years — potentially offering a safer, more accessible alternative to current pharmaceutical options for one of the world's most common chronic diseases.
Pull-Quote Suggestions:
"With roughly 2 billion adults worldwide affected by some degree of fatty liver disease, even a modestly effective cannabinoid-based treatment could represent one of the most significant therapeutic developments in metabolic medicine."
"For the millions of people already using CBD products for various health reasons, this study adds a potentially important new dimension to the conversation about cannabinoid supplementation."
"Clinical trials in human patients will be the next critical milestone."
Why It Matters: New research shows CBD and CBG improve liver health by boosting energy reserves and restoring cellular cleanup. Here's what the science reveals.